• PYC raises $146m through Accelerated Non-Renounceable Entitlement Offer
• Retail component raises $9.3m, with balance to be raised through underwriting
• Funds will progress PYC's pipeline of first-in-class drug candidates

PYC Therapeutics Limited (ASX:PYC) has announced the completion of the retail component of its $146 million Accelerated Non-Renounceable Entitlement Offer (ANREO or Entitlement Offer), which was announced to the ASX on 17 February 2025. The institutional component of the Entitlement Offer raised approximately $91 million, and the retail component has now raised $9.3 million, with the balance of the $146 million to be raised through the underwriting facility. The total funds raised will allow PYC to progress its entire pipeline of four first-in-class drug candidates with disease-modifying potential through major human data read-outs. The retail component of the Entitlement Offer was fully underwritten, and the balance of the funds will be raised through settlement of the Underwriting Agreement on or before 7 April 2025. The new shares subscribed for under the Retail Entitlement Offer are expected to be issued on 21 March 2025 and commence trading on the ASX on 24 March 2025.

The $146 million raised through the Entitlement Offer will fund PYC's pipeline of four first-in-class drug candidates with disease-modifying potential through major human data read-outs.